FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction

NCT05703997 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DIETARY_SUPPLEMENT: Cyclic, 5-day calorie restriction
DRUG: Atezolizumab

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborators

[object Object]
[object Object]